Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 26 July, 2012 and appeared in  MedicationType 1 DiabetesMedical DevicesIssue 636

Pramlintide + Insulin in Closed Loop System Improves Glucose Control

Adding pramlintide before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external closed-loop artificial pancreas system....

Advertisement

To examine whether preprandial injections of pramlintide, an analog of the naturally-occurring beta-cell peptide amylin, would improve postprandial glycemia by delaying gastric emptying, Stuart A. Weinzimer, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues treated eight patients with type 1 diabetes (15 to 30 years old) with a closed-loop insulin delivery system for 24 hours either alone or plus preprandial injections of 30 µg pramlintide.

The researchers found that the addition of pramlintide significantly increased the mean time to peak blood glucose (2.5 versus 1.5 hours). The addition of pramlintide also significantly reduced the mean magnitude of glycemic excursion (88 versus 113 mg/dL), with the reduction being particularly pronounced at lunch and dinner, when premeal insulin concentrations were higher.

"Pramlintide delayed the time to peak postprandial blood glucose and reduced the magnitude of prandial blood glucose excursions," Weinzimer and colleagues conclude. "Beneficial effects of pramlintide on closed-loop may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast."

Diabetes Care, June 2012
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 26 July, 2012 and appeared in  MedicationType 1 DiabetesMedical DevicesIssue 636

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

2013 Most Popular Articles:

Mortality Risk in Patients with Type 2 Diabetes
Posted May 23, 2013
Hypoglycemia Treatment and Prevention Related to Physical Activity
Posted May 31, 2013
Bacteria in the Gut Improves the Management of Obesity and Type 2 Diabetes
Posted May 23, 2013
Scientist Use Bone Marrow Stem Cells to Cure Type 1 Diabetes
Posted June 06, 2013
Simvastatin Can Reduce the Benefits of Exercise in Active Adults
Posted May 23, 2013
Artificial Sweeteners May Affect Blood Glucose Levels and Insulin Response
Posted June 06, 2013
Frequency of Blood Glucose Testing in Type 1's: How Often is Enough?
Posted June 13, 2013
Diabetes Epidemic Growing
Posted May 23, 2013
Co-Q10 May Offset Risk of Diabetes with Statin Use
Posted May 23, 2013
FDA Advisory Panel Votes to Remove Avandia's Highly Restrictive Label
Posted June 06, 2013

See more most popular…


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |
 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control



Search Articles On Diabetes In Control